|Bid||0.5900 x 2900|
|Ask||0.6050 x 800|
|Day's Range||0.5487 - 0.6050|
|52 Week Range||0.4600 - 15.7800|
|Beta (5Y Monthly)||-1.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 02, 2023 - May 08, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.74|
Subscribe to Yahoo Finance Plus to view Fair Value for VAPO
EXETER, N.H., March 17, 2023--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it was notified (the "Notice") on March 15, 2023 by the New York Stock Exchange, Inc. (the "NYSE") that the Company is not in compliance with the NYSE’s conti
Vapotherm (VAPO) delivered earnings and revenue surprises of 6.33% and 0.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
EXETER, New Hampshire, February 23, 2023--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced fourth quarter and fiscal year 2022 financial results.